Meeting
2021 Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) to reveal new opportunities and challenges in muscle-invasive bladder cancer (MIBC).
Authors
Laura Marandino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Laura Marandino , Russell Madison , Daniele Raggi , Filippo Pederzoli , Marco Bandini , Patrizia Giannatempo , Alberto Briganti , Francesco Montorsi , Jeffrey S. Ross , Andrea Necchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 479)
DOI
10.1200/JCO.2021.39.6_suppl.479
Abstract #
479
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Chiara Mercinelli
Poster
2023 ASCO Annual Meeting
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
First Author: Thomas W. Flaig
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas
Poster
2024 ASCO Genitourinary Cancers Symposium
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC).
First Author: Valentina Tateo